Cargando…
2165. Assessing the Impact of Meropenem Exposure on Ceftolozane/tazobactam-resistance Development in Pseudomonas aeruginosa using in vitro Serial Passage
BACKGROUND: Patients infected with Pseudomonas aeruginosa with difficult-to-treat resistance are likely to receive meropenem (MEM) as an empiric therapy before escalation to broader agent such as ceftolozane/tazobactam (C/T) after antimicrobial susceptibility data are available. We assessed if pre-e...
Autores principales: | Fouad, Aliaa, Nicolau, Samantha, Tamma, Pranita, Simner, Patricia J, Nicolau, David P, Gill, Christian M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677790/ http://dx.doi.org/10.1093/ofid/ofad500.1788 |
Ejemplares similares
-
Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2021) -
Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa
por: Gill, Christian M, et al.
Publicado: (2022) -
2253. Comparison of Outcomes Between Patients with and without Cystic Fibrosis Treated with Ceftolozane–Tazobactam for Pseudomonas aeruginosa Infections
por: Trisler, Michael J, et al.
Publicado: (2019) -
415 In Vitro Potency of Ceftolozane/Tazobactam against Pseudomonas aeruginosa Displaying Multidrug Resistance
por: Sutherland, Christina, et al.
Publicado: (2014) -
Successful Treatment of Multi-Drug Resistant Pseudomonas aeruginosa Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen
por: Patel, Ursula C., et al.
Publicado: (2016)